Author’s response to reviews

Title: Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent. The OPTimal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial

Authors:

Gérard Helft (gerard.helft@psl.aphp.fr)
Claude Le Feuvre (claude.lefeuvre@psl.aphp.fr)
Jean-Louis Georges (jgeorges@ch-versailles.fr)
Didier Carrie (carrie.dadier@chu-toulouse.fr)
Florence Leclercq (f-leclercq@chu-montpellier.fr)
Hélène Eltchaninoff (helene.eltchaninoff@chu-rouen.fr)
Alain Furber (alfurber@chu-angers.fr)
Fabrice Prunier (faprunier@chu-angers.fr)
Laurent Sebagh (lsebagh@gmail.com)
Simon Cattan (scattan@ch-montfermeil.fr)
Guillaume Cayla (guillaume.CAYLA@chu-nimes.fr)
Eric Vicaut (eric.vicaut@lrb.aphp.fr)
Jean-Philippe Metzger (jean-philippe.metzger@psl.aphp.fr)

Version: 3 Date: 6 February 2013

Author’s response to reviews: see over
Dear Sir,

We thank the reviewers for their additional comments and enclose our response together with our revised manuscript. We resubmit our manuscript to the journal for consideration.

Thank you

Yours faithfully,

Pr Gérard HELFT

Editorial requests

1. The title conforms to journal style for study protocol articles
2. The study protocol is formatted as outlined in the Instructions for authors

Reviewer’s report

1. Section “Inclusion/exclusion criteria”: we have corrected and have deleted “an” before “exclusion criteria (page 7).
2. Section “Study end points” 1st line, we have corrected: “all cause mortality” (page 8)
3. References: the two minor points have been fixed: comma after the year and full range of pages written for references 23 and 24 (page 20).